| Dr Sophia E Airhart, MD, FACC | |
|
6140 W Curtisian Ave Ste 102, Boise, ID 83704-0109 | |
| (208) 302-0000 | |
| (208) 302-0055 |
| Full Name | Dr Sophia E Airhart |
|---|---|
| Gender | Female |
| Speciality | Cardiovascular Disease (cardiology) |
| Experience | 14 Years |
| Location | 6140 W Curtisian Ave Ste 102, Boise, Idaho |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1427379825 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Saint Alphonsus Regional Medical Center | Boise, ID | Hospital |
| Saint Alphonsus Medical Center - Nampa | Nampa, ID | Hospital |
| Saint Alphonsus Medical Center - Ontario, Inc | Ontario, OR | Hospital |
| St. Alphonsus Medical Center - Baker City | Baker city, OR | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Saint Alphonsus Regional Medical Center Inc | 3476462359 | 509 |
| Saint Alphonsus Regional Medical Center Inc | 3476462359 | 509 |
News Archive
Severe adult obesity carries many risks to health, but until now, little has been known about childhood risk factors involved. Now, a multi-national study led by experts at Cincinnati Children's shows how adult severe obesity risk rates vary by sex, race and other factors identifiable in childhood.
New research published in The Lancet suggests that the publication of death rates for individual surgeons in England, launched for the first of a new group of 10 specialties last week, is unlikely to correctly identify poorly performing surgeons in some specialties, because low numbers of key operations lead to unreliable results.
Taiho Pharma Europe Ltd., a subsidiary of Japan based Taiho Pharmaceutical Co., Ltd., announced that it has submitted a Marketing Authorisation Application to the European Medicines Agency for TAS-102 (nonproprietary names: trifluridine and tipiracil hydrochloride), an oral combination anticancer drug intended for use in the treatment of refractory metastatic colorectal cancer (mCRC).
Celldex Therapeutics, Inc. today announced that the Company's first antibody-drug conjugate (ADC) product candidate, CDX-011 (formerly CR011-vcMMAE), for the treatment of locally advanced or metastatic breast cancer will be the subject of a poster presentation at the 2009 San Antonio Breast Cancer Symposium.
Afatinib (trade name: Giotrif) has been approved since September 2013 for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating EGF receptor mutations who have not been treated with an EGF receptor tyrosine-kinase inhibitor (EGFR TKI).
› Verified 9 days ago
| Entity Name | Saint Alphonsus Regional Medical Center Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1861676298 PECOS PAC ID: 3476462359 Enrollment ID: O20130801000623 |
News Archive
Severe adult obesity carries many risks to health, but until now, little has been known about childhood risk factors involved. Now, a multi-national study led by experts at Cincinnati Children's shows how adult severe obesity risk rates vary by sex, race and other factors identifiable in childhood.
New research published in The Lancet suggests that the publication of death rates for individual surgeons in England, launched for the first of a new group of 10 specialties last week, is unlikely to correctly identify poorly performing surgeons in some specialties, because low numbers of key operations lead to unreliable results.
Taiho Pharma Europe Ltd., a subsidiary of Japan based Taiho Pharmaceutical Co., Ltd., announced that it has submitted a Marketing Authorisation Application to the European Medicines Agency for TAS-102 (nonproprietary names: trifluridine and tipiracil hydrochloride), an oral combination anticancer drug intended for use in the treatment of refractory metastatic colorectal cancer (mCRC).
Celldex Therapeutics, Inc. today announced that the Company's first antibody-drug conjugate (ADC) product candidate, CDX-011 (formerly CR011-vcMMAE), for the treatment of locally advanced or metastatic breast cancer will be the subject of a poster presentation at the 2009 San Antonio Breast Cancer Symposium.
Afatinib (trade name: Giotrif) has been approved since September 2013 for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating EGF receptor mutations who have not been treated with an EGF receptor tyrosine-kinase inhibitor (EGFR TKI).
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Sophia E Airhart, MD, FACC 3340 E Goldstone Dr, Meridian, ID 83642-1026 Ph: (208) 367-5170 | Dr Sophia E Airhart, MD, FACC 6140 W Curtisian Ave Ste 102, Boise, ID 83704-0109 Ph: (208) 302-0000 |
News Archive
Severe adult obesity carries many risks to health, but until now, little has been known about childhood risk factors involved. Now, a multi-national study led by experts at Cincinnati Children's shows how adult severe obesity risk rates vary by sex, race and other factors identifiable in childhood.
New research published in The Lancet suggests that the publication of death rates for individual surgeons in England, launched for the first of a new group of 10 specialties last week, is unlikely to correctly identify poorly performing surgeons in some specialties, because low numbers of key operations lead to unreliable results.
Taiho Pharma Europe Ltd., a subsidiary of Japan based Taiho Pharmaceutical Co., Ltd., announced that it has submitted a Marketing Authorisation Application to the European Medicines Agency for TAS-102 (nonproprietary names: trifluridine and tipiracil hydrochloride), an oral combination anticancer drug intended for use in the treatment of refractory metastatic colorectal cancer (mCRC).
Celldex Therapeutics, Inc. today announced that the Company's first antibody-drug conjugate (ADC) product candidate, CDX-011 (formerly CR011-vcMMAE), for the treatment of locally advanced or metastatic breast cancer will be the subject of a poster presentation at the 2009 San Antonio Breast Cancer Symposium.
Afatinib (trade name: Giotrif) has been approved since September 2013 for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating EGF receptor mutations who have not been treated with an EGF receptor tyrosine-kinase inhibitor (EGFR TKI).
› Verified 9 days ago
Dr. Jennifer A Hofstra, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1055 N Curtis Road, Boise, ID 83706 Phone: 757-446-8920 Fax: 757-446-5242 | |
Dr. James Robert Polk, MD Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 1055 N Curtis Rd, Boise, ID 83706 Phone: 208-367-3104 | |
Dr. Michael Frederic Krug, M.D. Internal Medicine Medicare: Medicare Enrolled Practice Location: 500 W. Fort St, # 111, Boise, ID 83702 Phone: 208-422-1000 Fax: 208-422-1319 | |
Derrel V Walker, M.D. Internal Medicine Medicare: Medicare Enrolled Practice Location: 1055 N Curtis Road, Boise, ID 83706 Phone: 208-367-7350 Fax: 208-367-3951 | |
Dr. Janat E. O'donnell, MD Internal Medicine Medicare: Medicare Enrolled Practice Location: 500 W. Fort St., # 111, Boise, ID 83702 Phone: 208-422-1325 Fax: 208-422-1319 | |
Carl L Durning, MD Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 6094 W Emerald St, Boise, ID 83704 Phone: 208-367-6575 Fax: 208-367-6597 | |
Dr. Christopher J Goulet, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 6259 W Emerald St, Boise, ID 83704 Phone: 208-489-1900 Fax: 208-375-5286 |